Title of article
PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough
Author/Authors
Hynes، نويسنده , , Nancy E. and Dey، نويسنده , , Julien H. Meyer Jr.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2009
Pages
3
From page
353
To page
355
Abstract
Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issue of Cancer Cell, Junttila et al. show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which explains why trastuzumab is ineffective in some tumors.
Journal title
Cancer Cell
Serial Year
2009
Journal title
Cancer Cell
Record number
1336965
Link To Document